KOSDAQ IPO Class of 2023-2026: Where the Tenbaggers Actually Live — 259 Firms, 3 Buckets, 11 Names

Wed, 22 Apr 2026 10:30:00 +0900

📚 Series 2/2: KOSDAQ Structural Deep-Dive — series hub →

Second entry. Prior: Korea’s 2026 KOSDAQ Policy Package — A VC-Practitioner Ranking of the Ten Active Capital-Inflow Triggers mapped the money-in channels. This post asks the opposite question: once the money arrives, where does it actually compound? The answer from the 2023-2026 new-listing cohort is surprisingly concentrated.

TL;DR

Of 308 KOSDAQ new listings from 2023-2026, exactly 49 are SPACs (identified by “SPAC” in the Korean ticker name). Strip those out and the real operating universe is 259 firms.

From that 259:

39 firms (15%) have returned +100% or more since IPO
33 firms (13%) are down -50% or worse
53% are still below the IPO price
44% of the winners cluster in 3 sector buckets — R&D (pharma pipeline), semiconductors, medical devices. Those three buckets hold 48 firms, barely 19% of the universe, but 17 of the 39 tenbaggers came from them.

The single strongest numerical signal: firms with YoY revenue growth above 200% show a 57% tenbagger hit rate (4 of 7). The next bucket (50–200% growth) drops to 29%. Above 200% is effectively a structural filter.

Below: the full decomposition, then an 11-name Tier 1 shortlist to move into qualitative review.

1. Redefining the universe: SPACs cleanly removed

The cleanest SPAC filter is the Korean ticker-name rule: any listed shell with “스팩” (SPAC) in the name. That removes 49 names across four cohorts — most heavily from the 2024 cohort (36 SPACs alone).

Names sometimes flagged as “shells” but which are genuine operating businesses and therefore kept: LB Investment, HB Investment, Capstone Partners (all three are VC fund managers with real carry revenue), Hanpass (FX remittance fintech), Terra View. These stay in.

Cohort	Raw B-universe	After SPAC removal
2023 IPOs	101	92
2024 IPOs	123	87
2025 IPOs	79	75
2026 IPOs (YTD April)	5	5
Total	308	259

2. Year-by-year post-IPO performance (operating firms only)

Cohort	N	Median revenue (KRW bn)	Operating-profit firms	Median ADT20 (KRW bn/day)	Median return since IPO	+100% firms	+500% firms	Loser rate	Median current drawdown
2023	92	32.9	34%	1.15	+0.4%	11 (12%)	0	49%	-29%
2024	87	26.9	49%	1.24	-25.5%	16 (18%)	4	61%	-42%
2025	75	50.1	39%	2.02	-20.2%	12 (16%)	1	57%	-48%
2026	5	35.2	60%	24.70	-40.7%	0	0	60%	-41%

Three observations that pay off later:

2024 is the paradox cohort. Median return -25.5% (worst of any year), but all four +500% winners came from 2024 — Sceers Medical, D&D Pharmatech, Samhyun, HVM. Classic high-variance distribution: the median gets crushed while the right tail produces the biggest hits.
2025 is the “expensive IPO of mature companies” cohort. Median revenue 50.1B KRW (highest of any year — these were real companies at scale), but -48% median drawdown from peak. Pricing was rich; de-rating is mechanical. The distribution suggests 12–18 months out, this cohort should throw off re-entry opportunities at de-rated multiples.
Operating-profit rate isn’t a quality signal here. 2024 had the highest profitability (49% of listings profitable at IPO) yet the weakest post-IPO returns. High profitability at listing correlates with “mature companies priced near fair value” — exactly the opposite of where tenbaggers come from.

3. Sector bucket performance (N≥8, covering 139 of 259 firms)

Sector	N	Median rev (bn)	Profit rate	Median ROE	Median P/E	Median YoY growth	Median return	p90 return	+100% hits	Loser rate
R&D (bio pipeline)	18	4.3	11%	-44%	55	+9%	+51.5%	+312%	7	33%
Semiconductors	16	20.2	19%	-18%	59	+6%	+47.3%	+215%	5	38%
Medical devices	14	20.6	50%	+3%	49	+36%	+14.2%	+260%	3	43%
Electronic components	13	81.9	46%	0%	44	+9%	-6.7%	+80%	1	54%
Special-purpose machinery	22	29.9	32%	-2%	26	-3%	+0.2%	+52%	2	50%
General machinery	9	45.0	44%	-5%	26	+14%	-17.5%	+21%	0	67%
Software	36	19.6	28%	-8%	25	+11%	-17.6%	+67%	2	61%
Other chemicals (incl. EV battery)	11	28.5	82%	+8%	42	-8%	-42.2%	-17%	1	91%

Three winner buckets

Bio R&D + Semiconductors + Medical devices = 48 firms, 19% of universe, but 17 of the 39 +100% hits (44%). That concentration is not noise — it reflects a structural reality:

Bio R&D winners compound on clinical milestones and out-licensing deals, not current revenue. So a firm can have 4.3bn KRW median revenue and still hit +312% at the p90.
Semiconductor winners ride specific cycles: HBM-adjacent, AI-server SSD, wafer-back-end. Five listings hit +100% with median P/E of 59x — the market pays for the asymmetric call on new memory architectures.
Medical devices have the highest profitability (50% profit rate) and a +260% p90. That combination is rare. Korean medical devices with FDA approval + US distribution are structurally underpriced because the local market doesn’t know how to value US-scale med-tech.

Two loser buckets

Software (36 firms) + Other chemicals (11 firms) = 47 firms, explaining most of the loser population.

Software is the “AI premium paid at IPO” problem. 61% loser rate. Thin moats, low switching cost, and the “AI wrapper” narrative deflated as soon as enterprise buyers got sober in mid-2024.
Other chemicals is the 2차전지 (secondary battery) peak-out. 91% loser rate (10 of 11 down). Battery-material listings rode the 2022-2023 EV mania into IPO and then met the 2024-2025 demand correction head-on.

The middle zone

Special-purpose machinery, electronic components, general machinery — all “real revenue, boring multiples, mean-reverting performance.” Median revenue 30-82bn KRW (the biggest of any bucket) but median return near zero. This is the classic Korean KOSDAQ equipment/parts segment: legitimate businesses, cyclically priced, no asymmetric upside at IPO.

4. The DNA of the 39 winners

Looking across all +100% firms:

Characteristic	Count	Read
Operating-profit firms	13/39 (33%)	Profitability is not the signal. Two-thirds of tenbaggers are still losing money at IPO.
ROE > 10%	10	The 10 profitable-and-high-ROE winners are the “earnings-compounding” subset
YoY revenue growth > 50%	13	One-third have clear top-line explosions
Revenue ≥ 20bn KRW	22/38	58% have minimum size already
Revenue ≥ 100bn KRW	4/38	Large-revenue names are rare among tenbaggers — the universe favors smaller bases
Median P/E (profitable subset)	54.5×	Winners already trade at growth multiples

The single strongest signal: YoY revenue growth buckets

YoY revenue growth bucket	N	Median return	+100% hits	Hit rate
200%+	7	+106.8%	4	57%
50–200%	31	+8.5%	9	29%
20–50%	42	+10.5%	6	14%
0–20%	72	-8.2%	9	13%
-20–0%	66	-24.4%	6	9%
≤-20%	36	-22.8%	4	11%

The 57% hit rate for the 200%+ bucket is the single most concentrated signal in the data. Seven names — priority research targets. Caveat: n=7 is small; treat the number as a direction, not a probability estimate for the next cohort.

5. Top 10 winners — current state

Ticker	Sector	IPO	Return	Peak DD	Revenue (bn)	YoY growth
Sceers Medical	Medical device	2024-06	+1,111%	-31%	48.2	+495%
D&D Pharmatech	Bio R&D	2024-05	+1,011%	-27%	4.3	-62%
Samhyun	Auto parts	2024-03	+635%	-26%	95.0	-5%
HVM	Non-ferrous metals	2024-06	+614%	-19%	66.5	+47%
Rokit Healthcare	Medical supplies	2025-05	+526%	-38%	26.2	+100%
Tomocube	Optics	2024-11	+444%	-17%	11.3	+91%
Onconic Therapeutics	Bio R&D	2024-12	+421%	-14%	53.4	+261%
Sammi Metal	Metal fabrication	2025-12	+411%	-20%	73.8	-3%
Klobot	Software (robotics)	2024-10	+391%	-35%	41.4	+24%
Fadu	Semiconductor	2023-08	+338%	-14%	92.4	+112%

Notable pattern: 7 of the Top 10 are currently in -25% to -40% drawdown from their post-IPO peak. “One tenbagger move, then a 30% reset” is the modal pattern. From a re-entry-timing perspective, this is the window that matters most — the tenbagger already proved the structural story; the drawdown is about positioning, not about the thesis breaking.

Top losers — the opposite side: E8 (-87%, game/AI SW post-IPO dump), Chi Communication (-82%, China advertising), TDS Pharma (-80%, generics), DaeJin Advanced Materials (-77%, battery-materials loser), M83 (-69%, film production). Common pattern: story-driven overpricing → earnings vacuum → collapse.

6. From universe to shortlist: the Tier 1 11

Combining (a) the three winner buckets, (b) revenue in the 20-150bn KRW “meaningful but not saturated” zone, (c) clear top-line growth in the last 12 months, and (d) either ongoing drawdown (re-entry) or live catalyst (new positioning), the following 11 names emerge as Tier 1 for qualitative review.

Bio R&D (2)

#	Name	IPO	Rev (bn)	ROE	Return	DD	Thesis
1	Onconic Therapeutics	24-12	53.4	+24.6%	+421%	-14%	Subsidiary of Jeil Pharmaceutical. Jaktinib (reflux therapeutic) out-licensed to China and India, US trials advancing. Only profitable firm in the 18-stock bio R&D bucket with real revenue scale. Next leg needs additional out-licensing or US milestone.
2	D&D Pharmatech	24-05	4.3	-31.5%	+1,011%	-27%	GLP-1-based obesity and Parkinson’s pipeline. Already the biggest 2024 winner. Valuation stretched — next leg requires clinical data readout. Re-entry window is narrow.

Semiconductors (5)

#	Name	IPO	Rev (bn)	YoY	ROE	Return	3M	DD	Thesis
3	Green Resource	23-11	102.2	+452%	+15.9%	+151%	+193%	0%	Quartz/ceramic materials for semiconductor processes. Samsung/Hynix vendor. Revenue 4× explosion. Currently at fresh highs — entry should wait for correction.
4	Fadu	23-08	92.4	+112%	-131%	+338%	+186%	-14%	SSD controller SoC. Data-center/enterprise SSD (Meta-style) order recovery. Direct AI-server exposure.
5	Sapien Semiconductor	24-02	17.3	+116%	-33%	+140%	+11%	-14%	Micro-LED pixel driver IC. Apple Vision Pro / AR-glasses-class forward investment. Revenue inflection just starting.
6	Qualitas Semiconductor	23-10	5.4	-12%	-53%	+65%	+55%	-7%	SerDes (high-speed interconnect) IP. SK Hynix cooperation + HBM-adjacent SerDes demand. IP royalty model — likely J-curve inflection point.
7	Wavics	(listed in period)	40.7	—	—	—	+87%	—	RF GaN semiconductors. Defense + comms dual exposure. Only domestic mass producer of GaN-on-SiC.

Medical devices (4)

#	Name	IPO	Rev (bn)	YoY	ROE	Return	DD	Thesis
8	Sceers Medical	24-06	48.2	+495%	+52.8%	+1,111%	-31%	AI ECG monitoring device. Revenue + ROE + growth triple-compounding. Most structurally complete medical-device tenbagger. In -31% correction.
9	Livsmed	25-12	51.2	+89%	-21%	+17%	-36%	“ArtiSential” laparoscopic multi-articulating instrument. US/EU launch accelerating. Recent IPO + revenue 51bn + growth +89% + DD -36% — rare 4-factor alignment.
10	Nextbiomedical	24-08	16.5	+74%	0%	+135%	-37%	FDA-approved “Nexsphere” embolization product. US revenue ramp imminent.
11	Asterasys	25-01	37.9	+32%	+27.7%	+79%	-26%	HIFU ultrasound skin-treatment device “Liftera.” Korea / China / Middle East demand. Top-quartile ROE among profitable medical-device IPOs.

7. What this framework actually says

Question	Answer from the 259-firm backtest
Base rate of finding a +100% winner at KOSDAQ IPO	15% (39/259)
Base rate of finding a +500% winner	1.9% (5/259)
Worst cohort to chase	2024 at listing (median -25.5%, 61% losers — though the right-tail winners came from here)
Best cohort to hunt in right now	2025 (richest base — median revenue 50bn — currently at -48% median drawdown)
Single most predictive metric	YoY revenue growth ≥ 200% → 57% hit rate
Sectors to live in	Bio R&D, semiconductors, medical devices (44% of winners, 19% of universe)
Sectors to skip	Software (61% loser rate), secondary-battery chemicals (91% loser rate)

The framework isn’t a prediction engine. It’s a base-rate engine. It says: given how money has actually been made in new KOSDAQ listings over the last three years, these 11 names sit on more of the right factors than any others in the cohort. Qualitative review comes next — IR material, disclosure history, consensus positioning — and position sizing follows that.

8. Caveats and honest uncertainties

YoY growth percentages are noisy in bio R&D. Most have base revenues of 3-10bn KRW, so a “+7,800%” print (Algenomics) is the jump from 100M to 8bn — a milestone payment, not a business inflection. For bio names, look at absolute revenue + pipeline milestones, not YoY %.
Fundamentals are an 8-day snapshot. The ROE/P/E here come from the 2026-04-14 through 04-21 filings window. Next quarterly reports will reshuffle some of these names.
Green Resource, Fadu, Sonics — 3-month momentum ≥ +180%. Chasing these here carries a sharp drawdown risk. The Tier 1 placement reflects structural fit, not “buy now.”
Re-entry on past +1,000% winners. D&D Pharmatech and Sceers Medical have already delivered 10×. Another 5-10× from here requires a new catalyst — new market, new indication, new geography. Without it, the base case is mean reversion.
Consensus / target-price fields are empty in our data. Sell-side positioning isn’t reflected. IR contact and disclosure-level review is mandatory before sizing.

9. What’s next

This post closed the loop started by the VC-practitioner policy ranking: money-in channels → where the money actually compounds. Two pieces of the same structural view of KOSDAQ 2026.

Next on the research stack: Tier 1 single-name deep-dives — starting with the two names where the thesis is simultaneously (a) fundamentally strong, (b) technically in a constructive drawdown, and (c) within our existing framework. Onconic Therapeutics and Livsmed are the likely first targets.

Research and commentary only, not investment advice. Universe: KOSDAQ new listings 2023-2026 YTD April. SPAC filter: Korean ticker names containing “스팩.” Data window for fundamentals: 2026-04-14 to 2026-04-21 (KRX disclosure feed). All returns measured from IPO closing price to 2026-04-21 close.

New Listings on Korea Invest Insights